Skip to main content
Top
Published in: BMC Geriatrics 1/2023

Open Access 01-06-2023 | Parkinson's Dementia | Case Report

Deep venous thrombosis and hyponatremia associated with citalopram use for behavioral symptoms in Parkinson’s disease: a case report

Author: Afaf Albalawi

Published in: BMC Geriatrics | Issue 1/2023

Login to get access

Abstract

Background

Evidence is limited regarding the optimal therapeutic approach for neuropsychiatric symptoms associated with Parkinson’s disease dementia (PDD). Selective serotonin reuptake inhibitors (SSRIs) are widely used for mood disorders and behavioral symptoms in older adults with cognitive impairment, but they have limited efficacy in patients with PDD. The effect of SSRIs on hemostasis is also unclear. This report describes a patient with PDD who developed deep venous thrombosis (DVT) and hyponatremia after initiating citalopram treatment.

Case presentation

An 86-year-old woman with PDD presented to our emergency department with altered mental status, generalized weakness, and left lower leg swelling. Citalopram was begun 4 weeks previously for behavioral changes and was discontinued 2 days before presentation because of excessive fatigue. At presentation, her plasma sodium level was 123 mg/dL. Brain computed tomography showed age-related changes. Doppler ultrasound revealed a DVT in the left lower leg. The patient was treated with hypertonic saline and intravenous heparin. After normalization of her sodium, she was discharged on donepezil and apixaban. At follow-up, her sodium remained normal, and her cognition and behavior were noticeably improved.

Conclusion

Older adults with Parkinson’s disease are sensitive to adverse effects of psychotropic agents, including SSRIs, which are not recommended first-line agents for behavioral symptoms in PDD. Upon initiating SSRIs in older patients with functional decline and multiple comorbidities, physicians need to evaluate the patient’s risk factors for bleeding or thrombosis. Physical activities should also be maintained as much as possible.
Literature
1.
go back to reference Kimchi EZ, Lyketsos CG. Dementia and mild neurocognitive disorders. The textbook of geriatric psychiatry. Washington, DC: The American Psychiatric Publishing; 2015. Kimchi EZ, Lyketsos CG. Dementia and mild neurocognitive disorders. The textbook of geriatric psychiatry. Washington, DC: The American Psychiatric Publishing; 2015.
2.
go back to reference Stinton C, McKeith I, Taylor JP, Lafortune L, Mioshi E, Mak E, et al. Pharmacological management of lewy body dementia: a systematic review and meta-analysis. Am J Psychiatry. 2015;172:731–42.CrossRefPubMed Stinton C, McKeith I, Taylor JP, Lafortune L, Mioshi E, Mak E, et al. Pharmacological management of lewy body dementia: a systematic review and meta-analysis. Am J Psychiatry. 2015;172:731–42.CrossRefPubMed
3.
go back to reference Culo S, Mulsant BH, Rosen J, Mazumdar S, Blakesley RE, Houck PR, et al. Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial. Alzheimer Dis Assoc Disord. 2010;24:360–4.CrossRefPubMed Culo S, Mulsant BH, Rosen J, Mazumdar S, Blakesley RE, Houck PR, et al. Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial. Alzheimer Dis Assoc Disord. 2010;24:360–4.CrossRefPubMed
4.
go back to reference Kurne A, Ertugrul A, Yağcioğlu AEA, Yazici KM. Venous thromboembolism and escitalopram. Gen Hosp Psychiatry. 2004;26:481–3.CrossRefPubMed Kurne A, Ertugrul A, Yağcioğlu AEA, Yazici KM. Venous thromboembolism and escitalopram. Gen Hosp Psychiatry. 2004;26:481–3.CrossRefPubMed
5.
go back to reference Kim YW, Lee SH, Choi TK, Yook KH, Suh SY. A case of pulmonary embolism associated with escitalopram. Psychiatry Investig. 2007;4:52. Kim YW, Lee SH, Choi TK, Yook KH, Suh SY. A case of pulmonary embolism associated with escitalopram. Psychiatry Investig. 2007;4:52.
6.
go back to reference Hsu TW, Stubbs B, Liang CS, Chen TY, Yeh TC, Pan CC, et al. Efficacy of serotonergic antidepressant treatment for the neuropsychiatric symptoms and agitation in dementia: a systematic review and meta-analysis. Ageing Res Rev. 2021;69:101362.CrossRefPubMed Hsu TW, Stubbs B, Liang CS, Chen TY, Yeh TC, Pan CC, et al. Efficacy of serotonergic antidepressant treatment for the neuropsychiatric symptoms and agitation in dementia: a systematic review and meta-analysis. Ageing Res Rev. 2021;69:101362.CrossRefPubMed
7.
go back to reference Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311:682–91.CrossRefPubMedPubMedCentral Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311:682–91.CrossRefPubMedPubMedCentral
8.
go back to reference Skapinakis P, Bakola E, Salanti G, Lewis G, Kyritsis AP, Mavreas V. Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials. BMC Neurol. 2010;10:49.CrossRefPubMedPubMedCentral Skapinakis P, Bakola E, Salanti G, Lewis G, Kyritsis AP, Mavreas V. Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials. BMC Neurol. 2010;10:49.CrossRefPubMedPubMedCentral
9.
go back to reference Leentjens AF, Vreeling FW, Luijckx GJ, Verhey FR. SSRIs in the treatment of depression in Parkinson’s disease. Int J Geriatr Psychiatry. 2003;18:552–4.CrossRefPubMed Leentjens AF, Vreeling FW, Luijckx GJ, Verhey FR. SSRIs in the treatment of depression in Parkinson’s disease. Int J Geriatr Psychiatry. 2003;18:552–4.CrossRefPubMed
10.
go back to reference Jiang HY, Chen HZ, Hu XJ, Yu ZH, Yang W, Deng M, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2015;13:42–50e3.CrossRefPubMed Jiang HY, Chen HZ, Hu XJ, Yu ZH, Yang W, Deng M, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2015;13:42–50e3.CrossRefPubMed
11.
go back to reference Laporte S, Chapelle C, Caillet P, Beyens MN, Bellet F, Delavenne X, et al. Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: a meta-analysis of observational studies. Pharmacol Res. 2017;118:19–32.CrossRefPubMed Laporte S, Chapelle C, Caillet P, Beyens MN, Bellet F, Delavenne X, et al. Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: a meta-analysis of observational studies. Pharmacol Res. 2017;118:19–32.CrossRefPubMed
12.
go back to reference Adelborg K, Sundbøll J, Videbech P, Grove EL. The risk of thromboembolism in users of antidepressants and antipsychotics. Adv Exp Med Biol. 2017;906:351–61.CrossRefPubMed Adelborg K, Sundbøll J, Videbech P, Grove EL. The risk of thromboembolism in users of antidepressants and antipsychotics. Adv Exp Med Biol. 2017;906:351–61.CrossRefPubMed
14.
go back to reference Kunutsor SK, Seidu S, Khunti K. Response to commentary by Rhew and colleagues on: depression, antidepressant use, and risk of venous thromboembolism: systematic review and meta-analysis of published observational evidence. Ann Med. 2019;51:99–100.CrossRefPubMedPubMedCentral Kunutsor SK, Seidu S, Khunti K. Response to commentary by Rhew and colleagues on: depression, antidepressant use, and risk of venous thromboembolism: systematic review and meta-analysis of published observational evidence. Ann Med. 2019;51:99–100.CrossRefPubMedPubMedCentral
15.
go back to reference Zhou H, Tang Y, Yan Y, Yi Q, Du X, Liang Z. Antidepressant drugs and risk of venous thromboembolism: a case report and literature review. Klin Psikofarmakol Bül Bull Clin Psychopharmacol. 2011;21:237–41.CrossRef Zhou H, Tang Y, Yan Y, Yi Q, Du X, Liang Z. Antidepressant drugs and risk of venous thromboembolism: a case report and literature review. Klin Psikofarmakol Bül Bull Clin Psychopharmacol. 2011;21:237–41.CrossRef
16.
go back to reference Jacob S, Spinler SA. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. Ann Pharmacother. 2006;40:1618–22.CrossRefPubMed Jacob S, Spinler SA. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. Ann Pharmacother. 2006;40:1618–22.CrossRefPubMed
17.
go back to reference Wee R, Lim WK. Selective serotonin re-uptake inhibitors (SSRIs) and hyponatraemia in the elderly. Int J Geriatr Psychiatry. 2004;19:590–1.CrossRefPubMed Wee R, Lim WK. Selective serotonin re-uptake inhibitors (SSRIs) and hyponatraemia in the elderly. Int J Geriatr Psychiatry. 2004;19:590–1.CrossRefPubMed
18.
go back to reference Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.CrossRefPubMed Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.CrossRefPubMed
19.
go back to reference Aarsland D, Påhlhagen S, Ballard CG, Ehrt U, Svenningsson P. Depression in Parkinson disease–Epidemiology, mechanisms and management. Nat Rev Neurol. 2011;8:35–47.CrossRefPubMed Aarsland D, Påhlhagen S, Ballard CG, Ehrt U, Svenningsson P. Depression in Parkinson disease–Epidemiology, mechanisms and management. Nat Rev Neurol. 2011;8:35–47.CrossRefPubMed
20.
go back to reference Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev. 2012;2012:CD006504.PubMedPubMedCentral Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev. 2012;2012:CD006504.PubMedPubMedCentral
21.
go back to reference Kirchner V, Silver LE, Kelly CA. Selective serotonin reuptake inhibitors and hyponatraemia: review and proposed mechanisms in the elderly. J Psychopharmacol. 1998;12:396–400.CrossRefPubMed Kirchner V, Silver LE, Kelly CA. Selective serotonin reuptake inhibitors and hyponatraemia: review and proposed mechanisms in the elderly. J Psychopharmacol. 1998;12:396–400.CrossRefPubMed
Metadata
Title
Deep venous thrombosis and hyponatremia associated with citalopram use for behavioral symptoms in Parkinson’s disease: a case report
Author
Afaf Albalawi
Publication date
01-06-2023

Other articles of this Issue 1/2023

BMC Geriatrics 1/2023 Go to the issue